Day: May 15, 2025

Marex Group plc announces strong results for first quarter of 2025

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) — Marex Group plc (‘Marex’ or the ‘Group’; Nasdaq: MRX) a diversified global financial services platform, providing essential liquidity, market access and infrastructure services to clients in the energy, commodities and financial markets, today reported financial results for the first quarter (‘Q1 2025’). Ian Lowitt, Group Chief Executive Officer, stated, “Robust levels of client activity across our businesses and positive market conditions led to a strong performance in the first quarter of the year. Adjusted profit before tax grew 42% year-on-year, driven by strong revenue growth in all our business segments. This reflects the continued successful execution of our strategy to expand our geographic footprint and product capabilities, growing our client base, increasing...

Flagship Communities Real Estate Investment Trust Announces May 2025 Cash Distribution

Written by Customer Service on May 15, 2025. Posted in Dividend Reports And Estimates.

Not for distribution to U.S. newswire services or dissemination in the United States. TORONTO, May 15, 2025 (GLOBE NEWSWIRE) — Flagship Communities Real Estate Investment Trust (the “REIT”) (TSX:MHC.U; MHC.UN) announced today a cash distribution of US$0.0517 per REIT unit for the month of May 2025, representing US$0.62 per REIT unit on an annual basis. Payment will be made on or about June 16, 2025, to unitholders of record as of the close of business on May 30, 2025. Distributions paid to Canadian unitholders (and other non-U.S. unitholders) generally will be subject to U.S. withholding tax. Unitholders should consult their own tax advisors for advice with respect to the tax consequences of receiving a distribution from the REIT in their own circumstances. About Flagship Communities Real Estate Investment Trust Flagship Communities...

Microbix Reports Results for Q2 Fiscal 2025

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

Revenues of $5.3 million, Improved Gross Margin, and Positive Net Income MISSISSAUGA, Ontario, May 15, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its second quarter and first half of fiscal 2025 ended March 31, 2025 (“Q2” and “H1”). Sales for Q2 and H1 reflected differential growth between Antigens (up) and QAPs™ (down), alongside a markedly-improved gross margin. Management DiscussionResults for H1 were largely satisfactory, with recurring revenues increasing by 14% to $11.4 million, gross margin on those sales increasing by 10% to 61%, and net income of $0.9 million. Financial strength was also improved, with record cash & equivalents and overall liquidity, even after a material debt repayment and...

CDT Environmental Technology Files Annual Report on Form 20-F

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

Revenue of $29.8 million and net income of $1.4 million impacted by reduced project activity due to a slowdown in the PRC economy SHENZHEN, China, May 15, 2025 (GLOBE NEWSWIRE) — CDT Environmental Technology Investment Holdings Limited (NASDAQ:CDTG) (“CDT”, the “Company”, or “we”), a leading provider of waste treatment systems and services throughout China, announced to today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the “SEC”) on May 15, 2025. The annual report on Form 20-F, which contains CDT’s audited consolidated financial statements, can be accessed through the SEC’s website at www.sec.gov or CDT’s website at https://www.cdthb.cn. All amounts are expressed in US dollars unless otherwise stated. 2025 Financial ResultsTotal...

Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

– Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 – – Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter 2025 – – Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 – – Strengthened leadership team with appointments of Lisa von Moltke, M.D., Head of Research and Development and Chief Medical Officer, and Haley Laken, Ph.D., Chief Scientific Officer – – Cash, cash equivalents and investments of $314.2 million as of March 31, 2025, expected to provide financial runway into the fourth quarter of 2026 – WALTHAM, Mass., May 15, 2025 (GLOBE...

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force PEMGARDA revenue re-acceleration observed in Q2 2025 to date Invivyd continues to target near-term profitability (1H 2025) with existing cash and cash equivalents, anticipated growth of net product revenue, and continued reduction of operating expenses Since Emergency Use Authorization (EUA) of PEMGARDA in March 2024, no documented cases of anaphylaxis reported, across thousands of post-authorization doses VYD2311 Phase 1 clinical trial data read-out anticipated later in Q2 2025WALTHAM, Mass., May 15, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended March 31, 2025, and provided recent business...

American Shared Hospital Services Reports First Quarter 2025 Financial Results

Written by Customer Service on May 15, 2025. Posted in Public Companies.

Reports 17% Year over Year First Quarter Revenue Growth Conference Call Scheduled for 12:00 PM ET Today SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing and direct patient care services segments, today announced financial results for the first quarter ended March 31, 2025. Key Financial HighlightsQ1 2025 Revenue Increased 17% Compared to Q1 2024 Driven by Strategic Expansion and Operational Strength Q1 2025 Direct Patient Services Revenue Increased 224% Compared to Q1 2024 Due to the Acquisition of Rhode Island Centers and new Puebla, Mexico FacilityRay Stachowiak, Executive Chairman of American Shared Hospital...

Rubicon Organics Announces Appointment of Glen Ibbott as Interim CFO

Written by Customer Service on May 15, 2025. Posted in Public Companies.

VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX: ACB, Nasdaq: ACB) as its Interim Chief Financial Officer. Janis Risbin, current CFO, will be stepping away from her full-time role effective today. She will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Mr. Ibbott. “Glen’s leadership at Aurora Cannabis helped to build one of the largest cannabis companies in Canada. His expertise comes at an important time for Rubicon Organics as we...

Verde Announces Q1 2025 Results

Written by Customer Service on May 15, 2025. Posted in Public Companies.

(All figures are in Canadian dollars, unless stated otherwise. Average exchange rate in Q1 2025: C$1.00 = R$3.93) SINGAPORE, May 15, 2025 (GLOBE NEWSWIRE) — Verde AgriTech Ltd (TSX: “NPK”) (“Verde” or the “Company”) announces its financial results for the period ended March 31, 2025 (“Q1 2025”). As previously disclosed on March 28, 20251, product deliveries for the first half of 2025 were significantly impacted by the severe crisis in the Brazilian agricultural sector, which led to the insolvency of some of the country’s largest agricultural input suppliers and farming operations. Looking ahead to the second half of 2025, Verde is experiencing a recovery in orders as overall market credit risk declines, enabling stronger sales performance. In 2025, up to date, the Company has approved and delivered volumes equivalent to over...

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on May 15, 2025. Posted in Public Companies.

– Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death – On track to report preliminary data from Phase 1 monotherapy expansion cohorts of MICVO for 2L/3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy in second half of 2025, and 2L/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy in first half of 2026 – On track to report preliminary data from Phase 1 trial of MICVO in combination with pembrolizumab targeting multiple tumor types including 1L/2L HNSCC patients in second half of 2025 – Expected cash runway through data milestones and into second...

Day: May 15, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals